Key statistics
On Thursday, Incyte Corp (ICY:BRN) closed at 55.62, 0.00% below its 52-week high of 55.62, set on Dec 14, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 55.62 |
---|---|
High | 55.62 |
Low | 55.62 |
Bid | 55.41 |
Offer | 55.54 |
Previous close | 55.62 |
Average volume | -- |
---|---|
Shares outstanding | 192.60m |
Free float | 188.65m |
P/E (TTM) | 190.85 |
Market cap | 13.00bn USD |
EPS (TTM) | 0.3536 USD |
Data delayed at least 15 minutes, as of Dec 14 2023.
More ▼
Press releases
- Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress
- Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer
- Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium
- Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024
- Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma
- Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)
- Incyte to Present at Upcoming Investor Conferences
- Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
More ▼